Aspartame

If you have phenylketonuria (PKU), or cook for someone who does, read the warning below before anything else on this page. Aspartame is a source of phenylalanine. US law requires every product that contains it to say so on the label, and the daily intake figures later on this page do not apply to people with PKU.

What It Is

Aspartame is a high-intensity sweetener, about 200 times sweeter than table sugar according to FDA. In the EU it is E 951. On digestion it is broken down completely into three ordinary substances: two amino acids, phenylalanine and aspartic acid, and a small amount of methanol.

It is the most heavily studied and the most heavily contested sweetener on this site. Its US approval was revoked once and then reinstated, and in 2023 it was given a cancer hazard classification. Through all of it, no regulator’s acceptable daily intake has changed. This page sets out the evidence on each side.

A Warning for People with PKU

Phenylketonuria is a rare inherited disorder. Newborns are screened for it with a routine heel-prick test. People with PKU cannot break down phenylalanine normally, so it builds up to harmful levels, and aspartame is a common source of it in the diet.

The warning is mandatory. Under 21 CFR 172.804(d)(2), every product containing aspartame must carry the statement “PHENYLKETONURICS: CONTAINS PHENYLALANINE”, shown “prominently and conspicuously” in bold type on a clear contrasting background.

The acceptable daily intake does not apply to people with PKU. EFSA said this explicitly in its 2013 re-evaluation: people with PKU “require strict adherence to a diet low in phenylalanine”, whatever the ADI says. EFSA’s 2026 opinion kept that position. EFSA also modelled people who carry one copy of the PKU gene but do not have the disorder. For them, aspartame at the ADI posed no risk to a developing fetus. That margin does not extend to a woman who has PKU herself.

Neotame and advantame are both made from aspartame, and neither carries this warning. The reason is the tiny amount of phenylalanine they release, not a different structure. Their pages explain the arithmetic. If you manage PKU, work from your own clinical plan and the ingredient list.

Regulatory Status and History

In the US aspartame is an approved food additive, codified at 21 CFR 172.804. It went through the full petition process, like sucralose; it is not a GRAS notification. FDA has reviewed more than 100 toxicity studies on it.

Its US history is more contested than any other sweetener’s here:

• July 1974: FDA approves aspartame for dry foods and tabletop use. Within weeks there are two formal objections, one about brain tumours in rat feeding studies and one about phenylalanine.
• December 1975: FDA stays the approval, so aspartame cannot be sold, after an FDA task force questions some of the manufacturer Searle’s studies. In 1979 FDA concludes the problems found do not invalidate Searle’s aspartame studies.
• October 1980: FDA’s own Public Board of Inquiry revokes the 1974 approval, saying more study is needed on whether aspartame causes brain tumours.
• July 1981: the FDA Commissioner overturns the revocation after a scientific panel review finds “reasonable certainty aspartame did not cause brain tumors”. The manufacturer has to keep reporting post-market usage data, which it did through 2002.
• July 1983: approval extends to carbonated beverages; 1996: to general use across foods and beverages.
• 1986 to 1988: a petition to repeal the approvals is denied, the denial is challenged in an appeals court, and a lawsuit against the approvals is dropped.

In the EU, aspartame is authorised as E 951, food category by food category, each with its own maximum level. EFSA’s 2013 re-evaluation was, in EFSA’s words, “the first full risk assessment of aspartame” it had been asked to do. It concluded that the ADI of 40 mg/kg of body weight per day “is protective for the general population”, and its experts “ruled out a potential risk of aspartame causing damage to genes and inducing cancer”.

EFSA reassessed aspartame in an opinion published on 10 September 2026, as part of its review of the aspartame-acesulfame salt (E 962). It found no genotoxicity concern for aspartame or for DKP, its main degradation product. It confirmed the ADI of 40, and it concluded there is “no safety concern at the reported uses and use levels”. It also recommended that the European Commission review the arsenic and lead limits in aspartame’s specifications. If aspartame contained arsenic at the current limit of 3 mg/kg, the margin of exposure at the highest intakes would be “3 and < 1”, which EFSA called “a potential concern”. That is a calculation at the legal limit, not a measured level: EFSA cites no analytical data on how much arsenic or lead aspartame actually contains.

The ADI: Whose Number?

• FDA: 50 mg/kg of body weight per day
• JECFA (the joint FAO/WHO expert committee): 40 mg/kg bw/day
• EFSA: 40 mg/kg bw/day, confirmed in 2013 and again in 2026

Here FDA is the more permissive regulator, the opposite of sucralose, where FDA’s figure is the lowest. FDA’s timeline explains why. JECFA set 40 in April 1981. FDA set 50 in July 1983 “because of its review of the use of aspartame in carbonated beverages”. That was a figure for one food category, and it has stood since. Whichever number you use, name whose it is.

The margin is large under all three. WHO’s own worked example: a 70 kg adult drinking diet soft drinks with 200 to 300 mg of aspartame per can would need more than 9 to 14 cans a day to exceed the ADI.

EFSA’s 2026 modelling found no group of consumers over the ADI. In the scenario EFSA judged most appropriate, the highest 95th-percentile intake was 26.7 mg/kg bw/day, in toddlers, against the ADI of 40. Mean intake reached 7.7 mg/kg bw/day at most, in infants. More conservative scenarios put toddlers at 30.5 and 33.2, still below 40. EFSA counted consumers only, which it treats as the best approximation for people with diabetes, the group expected to eat the most sweeteners. None of these figures apply to people with PKU.

The 2023 Cancer Classification

On 14 July 2023, two WHO bodies announced two different kinds of finding in one joint statement, and most coverage reported them as a single contradiction.

IARC classified aspartame as “possibly carcinogenic to humans (Group 2B)”, on “limited evidence for cancer in humans (specifically, for hepatocellular carcinoma)” and limited evidence in experimental animals and on possible mechanisms. JECFA, the same day, reaffirmed the ADI of 40, finding “no sufficient reason to change” it. WHO explained the difference: IARC’s hazard identification is “the first fundamental step to understand the carcinogenicity of an agent”, while JECFA’s risk assessment estimates how likely harm is at real levels of exposure.

Group 2B is the third of IARC’s four tiers. It also includes aloe vera extract and pickled vegetables. The tier describes how strong the evidence is, not how large any risk is.

FDA did not stay neutral. It said it “disagrees with IARC’s conclusion”, having found “significant shortcomings in the studies on which IARC relied”, and noted that Health Canada and EFSA also consider aspartame safe at permitted levels.

EFSA’s 2026 opinion weighed the five human studies published since 2013. Only one found a statistically significant link with cancer: the French NutriNet-Santé cohort (Debras 2022), which reported a hazard ratio of 1.15 for overall cancer with higher aspartame intake. EFSA noted that “information bias and residual confounding could still be present”, and the study’s own authors wrote that causal links “cannot be established” from it (see the acesulfame potassium guide, which covers the same study). EFSA had low confidence in the human evidence for a link, and high confidence from animal studies that there is none. It concluded that it is “unlikely that exposure to aspartame (E 951) is associated with cancer in humans”. That is a risk judgement. IARC’s hazard classification has not changed.

What would change this picture: more epidemiological or mechanistic studies of liver cancer, which IARC and WHO said they would keep monitoring. If that evidence firms up, IARC could revise its classification or JECFA its ADI.

Methanol

Methanol is one of aspartame’s three digestion products (EFSA 2013), and the word alarms people. A 2026 peer-reviewed review states that the methanol released from a litre of aspartame-sweetened diet drink is lower than the methanol naturally present in the same volume of fruit juice. We have not yet checked that comparison against a primary toxicology source.

Heat, Calories and Blood Glucose

FDA states it plainly: aspartame “is not heat stable and loses its sweetness when heated, so it typically isn’t used in baked goods.” The law and the kitchen differ here. 21 CFR 172.804 does permit aspartame in baked goods and baking mixes, up to 0.5% of the weight of the ready-to-bake product. It is legal there but rarely practical.

Unlike saccharin or acesulfame potassium, aspartame does yield energy, because it is digested as amino acids. FDA: it “contains calories, but consumers will likely use less than they would of table sugar.” At about 200 times the sweetness of sugar, the amount used per serving is so small that its calories and carbohydrate round to nothing.

That is true of the pure compound, not of what you buy. Tabletop packets are bulked with dextrose or maltodextrin, which are ordinary, fast-digesting carbohydrate. If you are counting carbohydrate, count the carrier, not the aspartame. Our record has no dedicated glucose or insulin trial for aspartame, and nothing in it shows a blood-sugar benefit from choosing aspartame over another sweetener.

Comparison Note

Against acesulfame potassium: the same sweetness, about 200 times sugar, but Ace-K is heat stable and calorie-free, which is why the two are so often blended. Against neotame and advantame: both are made from aspartame, are far more potent, survive baking, and carry no PKU warning. Against saccharin: saccharin’s cancer flag went through the same arc and has closed, formally withdrawn in 2000, while aspartame’s is still open and being watched. Against sucralose: both are full food additives, and the two ADI disagreements run in opposite directions.

Every body that assesses aspartame’s risk, FDA, JECFA and EFSA among them, currently considers it safe at approved levels. IARC’s 2023 classification is about hazard, not risk, and it stands. The open question is whether IARC’s “limited evidence” grows stronger as more studies are done. For people with PKU none of that applies: the label warning is the number that matters.